Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win
Amgen and AstraZeneca’s co-developed blockbuster therapy Tezspire (tezepelumab) scored a Phase III win in a third epithelial-driven inflammatory disease –…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter…
-
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data
Bausch + Lomb has chosen to advance two of its pharmaceutical assets further down the clinical pipeline, despite one of…
-
Industry and federally backed cancer trials diverge in goals, analysis finds
New analysis has revealed that there are several distinctions between the goals of federal and industry-supported oncology clinical trials, which…
-
Analysts praise intismeran’s landmark Phase III win, look to further data
On 19 August, Moderna and MSD (Merck & Co) made history by netting the first late-stage victory for a cancer…
-
Chemo-free regimen touts breast cancer win amid targeted therapy shift
A new study has revealed that an all-targeted treatment regimen could hold potential as an effective frontline therapeutic option for…
-
AC Immune’s anti-inflammatory drug posts early-stage win
AC Immune’s anti-inflammatory therapy has netted a Phase I, first-in-human win in healthy volunteers, setting a positive precedent as the…
-
MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
MSD and Moderna are vying for the approval of their jointly developed personalised cancer vaccine, intismeran autogene, after the therapy…
-
Trump expected to nominate Heidi Overton as new FDA commissioner
US President Donald Trump is expected to put forward Heidi Overton as his choice for the next commissioner of the…
-
Podcast: Bringing diversity to Alzheimer’s trials
In recent years, the Alzheimer’s disease market has seen several developments, including the debut of the first disease-modifying therapies (DMTs),…